A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Diabetic Macular Edema

Interventions

GENETIC

SKG0106 intravitreal injection dose level 1, 2 or 3

SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.

Trial Locations (2)

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors

collaborator

Lanyue Biotech (Hangzhou) Co., Ltd.

INDUSTRY

lead

Wang Min

OTHER